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Neuroendocrine 
tumours in children
• Relatively rare amongst children
• Majority occur sporadically and are non-hereditary
• Despite this, carcinoid tumours may also be 
associated with hereditary syndromes
• Most endocrine tumours in children 
o Clinically benign
o Low grade malignancies
• NETS
o Known for late diagnoses
• Liver or bone metastases
• Multi year history of symptoms before malignancy identified
o Few reports in children
• At least 10% of children have metastatic disease at presentation
Distribution of NETS in children 
and young adults <30 years
Tumour type Percentage of NET in this age group
Bronchial NET 28
Medullary carcinoma of the breast 18
Appendiceal NET 18
Colon and rectal NET 9
Jejunal and ileal NET 5
Small cell carcinoma (ovary) 5
Unknown primary NET 5
Pancreatic and gastric NET * 4
Medullary carcinoma thyroid * 4
Small cell carcinoma (cervix) 4
Other NETs
• Phaeochromocytoma
o MEN 2A
o MEN 2B
o VHL disease
o NF1
o Peak incidence between 9 -12 years of age 
• Nearly 10% occur in children
• 10% of these are malignant
• Paranganglioma
o Extra adrenal in origin
o Parasympathetic nervous system
Screening
• MEN 1 & 2 and VHL
o Autosomal dominant
• Only one mutation in one pair of genes is needed to cause the 
condition
• 50% chance of having a boy or a girl with the same condition
o Most commonly present in early adulthood and onwards
o Can now target individuals at risk
o Genetic screening allows the children from affected families who have 
NOT inherited the mutation
• Reassured
• Avoid regular clinical monitoring
• Issues re: Informed consent, counselling and confidentiality

Family trees
• Biological relationships between family
members
• Any medical conditions
o Reveal patterns of inheritance
o Assesses likelihood of genetic diseases in relatives
o Individuals can then be offered targeted surveillance
Including children
• Builds rapport with patients
o Develop trust, to ask questions
o Correct any misconceptions about symptoms

MEN 1
• Parathyroid tumours
o 90% of MEN1 patients
• Pituitary tumours
o 30% of MEN1 patients
• Pancreatic Islet cell 
tumours
o 75% of MEN1 patients
• Carcinoid tumours
o Chest / stomach
o Lipomas
o Thyroid
o Adreno-cortical tumours
MEN 1 screening in 
children
• Children of an 
identified MEN1 patient
o Screened genetically initially
o Screened clinically from age 10
• Annual measurements
o Calcium, PTH
o Pancreatic 
polypeptide and 
gastrin
• Imaging
o Prolactin, IGF-1
• Imaging
Chromosome 11
MEN 2a
• Thyroid gland
o MTC
o Child with a known MEN2a 
gene change
• Total thryoidectomy before 
age of 5yrs
o Newly diagnosed adults
• Screen children asap
• Parathyroid glands
• Adrenal glands
o Phaeochromcytomas
• 24hr urine collections
MEN 2b
• Thyroid gland tumours
• Phaeochromocytomas
• Benign lumps on the lips,
in the mouth and throughout 
the gut
o Children
• More likely to have feeding 
problems, bowel problems
o Present with FTT
MEN 2 screening 
• Screened genetically
o MTC assoc with MEN2b
• Can occur in first year of 
life
o MEN2b – age 1yr
o MEN2a – age 5yrs
• Clinical screening
o Thyroid
o Adrenal
Chromosome 10
Patient support
• AMEND
o UK Patient support group
o www.amend.org.uk
Children’s area

Phaeochromocytomas
Adrenal Gland A & P
• Adrenal cortex
o Outer portion
• Adrenal medulla
o Inner portion
Adrenal Cortex
• Mineralocorticoids
o ALDOSTERONE
• Helps regulate BP by 
controlling how much salt 
is retained in the body
• Glucocorticoids
o CORTISOL
• The body’s natural steroid, 3 
main functions:
o Helps control the blood 
sugar level
o Helps the body deal 
with stress
o Helps to control BP and 
blood circulation
• Sex Steroids /  Androgens
o DHEA
o DHEA-S
o Androstenedione
• Secondary sexual 
characteristics
Adrenal Medulla
• Catecholamines
o Adrenaline
• Released in response to signals from the sympathetic 
nervous system
• Increases 
o Blood sugar
o Muscle glycogen breakdown
o Blood flow to muscle
o Respiration
o Noradrenaline
• Similar effects to adrenaline, as well as maintains BP
o Dopamine
• Precursor to adrenaline and noradrenaline
o Neurotransmitter
Phaeochromocytoma
• Neuroendocrine tumour
• Usually benign, can be 
malignant
• Excretes excess 
catecholamines
• Uncommon cause of ­
BP \ can easily be 
missed
• We have occasional 
bursts of cats when we 
are upset or stressed
o Those with phaeos have 
it all the time
Phaeochromocytoma
• Only present in 10% of VHLs
• French study in the 90s
o Phaeos were the first 
manifestation of VHL disease 
in 51% of pts
o Only manifestation for up to 
age 21 yrs, or even indefinitely
• Easy to miss the diagnosis
• Usually arise in the adrenals, 
may also originate in 
paraganglia outside the 
adrenals
Phaeochromocytoma
• Symptoms ?
o ­BP
o Headache
o Perspiration / episodic 
sweating
o Palpitations
o Anxiety attacks
• May be incorrectly 
attributed to anxiety or 
depression
• Can cause life 
threatening conditions
o Hypertensive crisis
o Mets - Stroke
o Cardiac failure - MI
Von Hippel-Lindau disease
• Chromosome 3
• Tumour suppressor 
gene
• Can identify the gene
o Pre-symptomatic screening
• Autosomal dominant
o Each child of an affected 
individual has a 1 in 2 chance 
(50%) to inherit the gene 
alteration
• Children referred
o Fellow adult endocrine teams 
managing in their 
affectedparent
Von Hippel Lindau disease
• Incidence
o 1 in 40,000
o Average age of presentation
• 26 yrs of age
• Haemangioblastomas
o Brain, spinal cord, retina
• Renal cysts
• Phaechromocytomas
Chromosome 3
Screening in VHL
• Ophthalmology review
o Fundoscopy screening
• Adrenals
o Phaeochromocytomas
• Renal carcinomas
o Now leading cause of death 
amongst VHL patients
• Successful treatment for 
CNS haemangioblastomas
• Imaging
• Genetics
o Analysis of the index case is key 
to identifying  further members 
of the family at risk
o Can be done from age 5yrs
• Enable clinical screening
Reduction in morbidity compared 
to their parents
Case study
• Male child Tom
• DOB 10.11.01
• Family history of VHL
• Positive for the familial mutation in exon 3 of the VHL 
gene
• Commenced screening programme 
o 2006 age 5yrs
Family history
• Paternal aunt
o Bilateral phaechromocytomas
7 and 21yrs
o Cerebral haemangioblastoma
16yrs
o Retinal haemangioblastoma
18yrs
o Right renal carcinoma 28yrs
o Pancreatic NET 36yrs
• Cousin (female)
o Bilateral phaechromocytomas
12yrs and 14yrs
o Pancreatic NET 19yrs
• Brother
o Age 3yrs
• Father
o Retinal angiomatosis
o Bilateral phaechromocytomas
23yrs
o Cervical spine 
haemangioblastoma 33yrs
o Bilateral renal cell carcinomas 
34 7 35yrs
• Half-brother
o Right phaechromocytoma age 
14yrs
• 3 year old son

Clinical screening
• 2011
o February
• 477nmol/day
• 2012
o Lesion seen on abdominal MRI
o Repeat MRI with contrast
o MIBG scan
• 2007, 2008, 2009
o All normal
• 2010
o January
o Urine catecholamine 
(noradrenaline) slightly elevated
• 370nmol/day (N=below 194)
o Repeat and watch as 
asymptomatic
o May
• 433nmol/day
o June
• MRI adrenal normal
o October
• 372nmol/day
MRI Abdomen 12.10.12
• Review of imaging  for endocrine VHL MDT 31.10.2012
• There is a 3cm MIBG positive paraganglioma in the upper 
retroperitoneum interposed between in the aorta, IVC and 
portal vein. No local invasion seen. Slow increase in size since 
2008.
• Small areas of soft tissue in the distal aorto-caval region but 
these are currently indeterminate.
• Normal kidneys, adrenals and pancreas
• Excision of paraganglioma January 2013, age 11yrs

Clinical management
• April 2012
o Paraganglioma
• Small
• No plans for surgery
• Intermittent symptoms and continued raised catecholamines
• Commence Doxazocin 0.5mg once daily
o Increase to twice a day after a week if tolerated
o Continue until surgery planned
o Doxazocin
• Alpha blockade
o Reduces BP
MRI Abdomen 6.8.14
• New 9mm peripherally enhancing left adrenal 
nodule which demonstrates restricted diffusion likely 
to represent a small phaechromocytoma.

Clinical management
• 2014
o November age 13yrs
• Now wants to be seen without his Mum
• ? Phaeochromocytoma
• Tom very stressed and upset
• Psychological input offered 
• 2015
o Further imaging..
MRI Pancreas 23.2.15
• The anterior lesion in the tail of the pancreas is still 
present and demonstrates an arterial blush. 
• This remains suggestive of an islet cell tumour. 
• No other pancreatic lesion is demonstrated.

MRI adrenals 14.7.15
• The right adrenal mass in the body of the adrenal 
has further increased in size now measures 13 mm. 
• The left adrenal nodule in the lateral limb is stable 
measuring 15 mm.
• Both lesions have similar properties and the 
appearances are in keeping with small 
phaeochromocytomas


Continued management
• 2015
o July
o Bilateral phaeochromocytomas
o Now proceed to surgery
o December had surgery
• 2016
o April – surgical follow up
o As you know he underwent a right laparoscopic adrenalectomy for a 
pheochromocytoma within the Von Hippel Lindau syndrome in December last year, 
from which he made a rapid and uncomplicated post-operative recovery.
o On examination today, all incisions have healed well.
o We knew pre-operatively that he had bilateral phaeochromocytomas however the 
right was the largest and we hoped to proceed with a staged adrenalectomy to 
preserve adrenal function for as long as possible.  
o Unfortunately, post-operative urinary nor-metadrenaline has not decreased 
substantially although his mother tells me he remains normotensive and 
asymptomatic.
o I discussed the findings with him and his mother today and I have suggested that he 
seeks an early appointment with the paediatric endocrine team to discuss the 
potential for going back on to doxazosin.  He particularly would like to avoid further 
surgery for at least a year.  He is of course in his GSCE year currently.
Auxology
Height Weight 
Potential further 
managment
• Bilateral adrenalectomy
o Hydrocortisone replacement
Conclusion
• Management of children with NETs very complex
• Importance of screening emphasised
o Genetics and clinical
• Inform families
• Reduce need for screening
• Reduction in morbidity compared to their parents
• Can screen from age 5yrs
o MEN2b genetics from age 1yr
• Potentials for further management
o Nursery / School
• Hydrocortisone management
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